FRE Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €24.96 |
52 Week High | €31.10 |
52 Week Low | €23.99 |
Beta | 1.09 |
1 Month Change | -3.96% |
3 Month Change | -11.93% |
1 Year Change | 3.23% |
3 Year Change | -34.33% |
5 Year Change | -52.34% |
Change since IPO | -68.68% |
Recent News & Updates
Recent updates
Shareholder Returns
FRE | AT Healthcare | AT Market | |
---|---|---|---|
7D | 0.2% | 0.7% | 1.5% |
1Y | 3.2% | -1.9% | 6.5% |
Return vs Industry: FRE exceeded the Austrian Healthcare industry which returned -2.5% over the past year.
Return vs Market: FRE underperformed the Austrian Market which returned 6.9% over the past year.
Price Volatility
FRE volatility | |
---|---|
FRE Average Weekly Movement | 3.2% |
Healthcare Industry Average Movement | 5.0% |
Market Average Movement | 3.3% |
10% most volatile stocks in AT Market | 4.8% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months.
Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1912 | 193,865 | Michael Sen | https://www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
FRE fundamental statistics | |
---|---|
Market cap | €14.05b |
Earnings (TTM) | €353.00m |
Revenue (TTM) | €22.30b |
39.8x
P/E Ratio0.6x
P/S RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FRE income statement (TTM) | |
---|---|
Revenue | €22.30b |
Cost of Revenue | €17.24b |
Gross Profit | €5.06b |
Other Expenses | €4.71b |
Earnings | €353.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | 0.63 |
Gross Margin | 22.68% |
Net Profit Margin | 1.58% |
Debt/Equity Ratio | 70.4% |
How did FRE perform over the long term?
See historical performance and comparison